Johnson & Johnson
Market Cap
US$337.0b
Last Updated
2019/10/19 23:37 UTC
Data Sources
Company Financials +
Executive Summary
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide.
Snowflake
Fundamentals
Established dividend payer with proven track record.
Similar Companies
Share Price & News
How has Johnson & Johnson's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-2.8%
JNJ
-0.06%
US Pharmaceuticals
0.4%
US Market
1 Year Return
-8.2%
JNJ
-8.0%
US Pharmaceuticals
6.9%
US Market
Return vs Industry: JNJ matched the US Pharmaceuticals industry which returned -8% over the past year.
Return vs Market: JNJ underperformed the US Market which returned 6.9% over the past year.
Shareholder returns
| JNJ | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.8% | -0.06% | 0.4% |
| 30 Day | -1.9% | -0.9% | -1.1% |
| 90 Day | -2.0% | -1.7% | -0.5% |
| 1 Year | -5.6%-8.2% | -5.8%-8.0% | 9.3%6.9% |
| 3 Year | 22.0%12.6% | 18.3%10.0% | 45.8%36.4% |
| 5 Year | 42.0%23.8% | 22.1%9.2% | 62.9%45.1% |
Price Volatility Vs. Market
How volatile is Johnson & Johnson's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Are Investors Undervaluing Johnson & Johnson (NYSE:JNJ) By 41%?3 weeks ago | Simply Wall St
The Johnson & Johnson (NYSE:JNJ) Share Price Is Up 23% And Shareholders Are Holding On1 month ago | Simply Wall St
Need To Know: Johnson & Johnson (NYSE:JNJ) Insiders Have Been Selling SharesValuation
Is Johnson & Johnson undervalued compared to its fair value and its price relative to the market?
49.6%
Undervalued compared to fair value
Share Price vs. Fair Value
Undervalued: JNJ ($127.7) is trading below our estimate of fair value ($253.23)
Significantly Undervalued: JNJ is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: JNJ is poor value based on its PE Ratio (19.6x) compared to the Pharmaceuticals industry average (16x).
PE vs Market: JNJ is poor value based on its PE Ratio (19.6x) compared to the US market (17.6x).
Price to Earnings Growth Ratio
Low PEG Ratio: JNJ is poor value based on its PEG Ratio (2.9x)
Price to Book Ratio
PB vs Industry: JNJ is overvalued based on its PB Ratio (5.6x) compared to the US Pharmaceuticals industry average (2.9x).
Next Steps
Future Growth
How is Johnson & Johnson forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
6.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: JNJ's forecast earnings growth (6.9% per year) is above the savings rate (2.7%).
Earnings vs Market: JNJ's earnings (6.9% per year) are forecast to grow slower than the US market (14.6% per year).
High Growth Earnings: JNJ's earnings are forecast to grow, but not significantly.
Revenue vs Market: JNJ's revenue (4.1% per year) is forecast to grow slower than the US market (7.2% per year).
High Growth Revenue: JNJ's revenue (4.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: JNJ's Return on Equity is forecast to be high in 3 years time (32.8%)
Next Steps
Past Performance
How has Johnson & Johnson performed over the past 5 years?
-10.4%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: JNJ's earnings have declined by -10.4% per year over the past 5 years.
Accelerating Growth: JNJ's earnings growth over the past year (1017.4%) exceeds its 5-year average (-10.4% per year).
Earnings vs Industry: JNJ earnings growth over the past year (1017.4%) exceeded the Pharmaceuticals industry 24.3%.
Return on Equity
High ROE: JNJ's Return on Equity (28.3%) is considered high.
Return on Assets
ROA vs Industry: JNJ has a higher Return on Assets than the Pharmaceuticals industry average last year.
Return on Capital Employed
ROCE Improving: JNJ has not improved its Return on Capital Employed over the past 3 years.
Next Steps
Financial Health
How is Johnson & Johnson's financial position?
Financial Position Analysis
Short Term Liabilities: JNJ's short term assets ($41.8B) exceeds its short term liabilities ($31.4B)
Long Term Liabilities: JNJ's short term assets (41.8B) do not cover its long term liabilities (63.0B)
Debt to Equity History and Analysis
Debt Level: JNJ's debt to equity ratio (48.4%) is considered high
Reducing Debt: JNJ's debt to equity ratio has increased from 20.1% to 48.4% over the past 5 years.
Debt Coverage: JNJ's debt is well covered by operating cash flow (74.8%).
Interest Coverage: JNJ's interest payments on its debt are well covered by EBIT (1916.9x coverage).
Balance Sheet
Inventory Level: JNJ has a low level of unsold assets or inventory.
Debt Coverage by Assets: JNJ's debt is covered by short term assets (assets are 1.420810x debt).
Next Steps
Dividend
What is Johnson & Johnson's current dividend yield, its reliability and sustainability?
2.97%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: JNJ's dividend (2.98%) is higher than the bottom 25% of dividend payers in the US market (1.45%).
High Dividend: JNJ's dividend (2.98%) is low compared to the top 25% of dividend payers in the US market (3.73%).
Stable Dividend: JNJ's dividends per share have been stable in the past 10 years.
Growing Dividend: JNJ's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (56.9%), JNJ's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: JNJ's dividends in 3 years are forecast to be well covered by earnings (42.3% payout ratio).
Next Steps
Management
What is the CEO of Johnson & Johnson's salary, the management and board of directors tenure and is there insider trading?
7.0yrs
Average management tenure
CEO
Alex Gorsky (59yo)
7.5yrs
Tenure
US$20,097,572
Compensation
Mr. Alex Gorsky has been the Chairman and Chief Executive Officer of Johnson & Johnson since December 28, 2012 and April 26, 2012 respectively. Mr. Gorsky served as the Chief Operating Officer and Head of ...
CEO Compensation Analysis
Compensation vs. Market: Alex's total compensation ($USD20.10M) is about average for companies of similar size in the US market ($USD11.18M).
Compensation vs Earnings: Alex's compensation has been consistent with company performance over the past year.
Management Age and Tenure
7.0yrs
Average Tenure
57yo
Average Age
Experienced Management: JNJ's management team is seasoned and experienced (7 years average tenure).
Board Age and Tenure
6.9yrs
Average Tenure
67.5yo
Average Age
Experienced Board: JNJ's board of directors are considered experienced (6.9 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Shares | 3,000 |
| Max Price | US$139.68 |
| Entity | Individual |
| Role | Lead Director Lead Independent Director |
| Shares | 748 |
| Max Price | US$133.76 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 1,000 |
| Max Price | US$133.91 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 2,000 |
| Max Price | US$134.37 |
| Entity | Individual |
| Role | Chief Accounting Officer Controller & Chief Accounting Officer |
| Shares | 3,643 |
| Max Price | US$147.31 |
| Entity | Individual |
| Role | Chief Accounting Officer Controller & Chief Accounting Officer |
| Shares | 8,441 |
| Max Price | US$145.15 |
Ownership Breakdown
Management Team
Paul Stoffels (57yo)
Chief Scientific Officer
- Tenure: 7yrs
- Compensation: US$10.59m
Mike Ullmann (60yo)
Executive VP & General Counsel
- Tenure: 7.8yrs
- Compensation: US$5.34m
Alex Gorsky (59yo)
Chairman & CEO
- Tenure: 7.5yrs
- Compensation: US$20.10m
Michael Sneed
Executive VP of Global Corporate Affairs & Chief Communication Officer
- Tenure: 7.8yrs
Guy Lebeau
Group Chairman of MD&D Business - EMEA
- Tenure: 0yrs
Joaquin Duato (56yo)
Vice Chairman of Executive Committee
- Tenure: 8.8yrs
- Compensation: US$9.28m
Peter Fasolo (56yo)
Executive VP & Chief Human Resources Officer
- Tenure: 3.5yrs
- Compensation: US$3.62m
Ron Kapusta (60yo)
Controller & Chief Accounting Officer
- Tenure: 4yrs
Joe Wolk (52yo)
Executive VP & CFO
- Tenure: 1.3yrs
- Compensation: US$2.71m
Chris DelOrefice
Vice President of Investor Relations
- Tenure: 1.2yrs
Board Members
Bill Perez (71yo)
Independent Director
- Tenure: 12.3yrs
- Compensation: US$339.94k
Ron Williams (70yo)
Independent Director
- Tenure: 8.3yrs
- Compensation: US$339.94k
Chuck Prince (69yo)
Independent Director
- Tenure: 13.7yrs
- Compensation: US$339.94k
D. Davis (67yo)
Independent Director
- Tenure: 5.3yrs
- Compensation: US$324.94k
Anne Mulcahy (67yo)
Lead Independent Director
- Tenure: 6.8yrs
- Compensation: US$354.94k
Ian Edward Davis (68yo)
Independent Director
- Tenure: 9.3yrs
- Compensation: US$299.94k
Alex Gorsky (59yo)
Chairman & CEO
- Tenure: 7.5yrs
- Compensation: US$20.10m
Mark McClellan (55yo)
Independent Director
- Tenure: 6yrs
- Compensation: US$299.94k
Mary Beckerle (64yo)
Independent Director
- Tenure: 4.3yrs
- Compensation: US$339.94k
A. Washington (68yo)
Independent Director
- Tenure: 6.9yrs
- Compensation: US$319.94k
Company Information
Johnson & Johnson's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Johnson & Johnson
- Ticker: JNJ
- Exchange: NYSE
- Founded: 1887
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$337.021b
- Shares outstanding: 2.64b
- Website: https://www.jnj.com
Number of Employees
Location
- Johnson & Johnson
- One Johnson & Johnson Plaza
- New Brunswick
- New Jersey
- 8933
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| JNJ | XTRA (XETRA Trading Platform) | Yes | Common Stock | DE | EUR | Jan 1968 |
| JNJ | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Jan 1968 |
| JNJ * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Jan 1968 |
| JNJ | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jan 1968 |
| JNJ | SWX (SIX Swiss Exchange) | Yes | Common Stock | CH | CHF | Jan 1968 |
| JNJ | BVL (Bolsa de Valores de Lima) | Yes | Common Stock | PE | USD | Jan 1968 |
| JNJ | BVC (Bolsa de Valores de Colombia) | Yes | Common Stock | CO | COP | Jan 1968 |
| JNJ | SNSE (Santiago Stock Exchange) | Yes | Common Stock | CL | USD | Jan 1968 |
| JNJ | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | Jan 1968 |
| JNJ | BASE (Buenos Aires Stock Exchange) | CEDEAR EACH REP O.20 ORD SHS | AR | ARS | Jan 2001 | |
| JNJB34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EA REPR 1 COM SHS | BR | BRL | Aug 2012 |
Biography
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceuti ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/19 23:37 |
| End of Day Share Price | 2019/10/18 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.